Dave Lashmet is the Editor of Stansberry Venture Technology, a monthly advisory that takes a "venture capitalist" approach to investing. Dave seeks out small-cap speculative stocks with outstanding breakout growth potential.

He was one of the first employees at Stansberry Research back in the early days of the business. His unique insight into new technologies has led to some of the biggest gains in the company's history.

Dave has spent 10-plus years teaching and writing about medicine and technology at major research universities. He has also conducted research at some of the most important facilities in North America, including Harvard Medical School, Johns Hopkins University, the Massachusetts Institute of Technology, and the Canadian Centers for Disease Control, just to name a few.

He is also credited as an inventor on three issued U.S. patents (in high-tech hardware and software), and as a co-inventor on three virtual-reality patent applications. As of 2023, these applications are under review by the U.S. Patent and Trademark Office.

Dave returned to Stansberry Research in 2014 after a stint at a consumer electronics company where he managed a team of experts. His work there took him around the world, delivering presentations in Germany, Taiwan, China, Canada, New York, and Los Angeles. He has even delivered a briefing before a congressional delegation. Dave is also an Analyst for Stansberry's Investment Advisory.